SCHEMBL695169

SCHEMBL695169

Clc1[nH]n[c]c1Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.41
ALDH1A1 P00352 4/20 0.39
TYMP P19971 1/20 0.39
NR1H2 P55055 3/20 0.38
NR1H3 Q13133 2/20 0.38
DAO P14920 1/20 0.36
GAA P10253 1/20 0.36
ALPL P05186 1/20 0.36
TAAR1 Q96RJ0 3/20 0.35
HRH3 Q9Y5N1 1/20 0.35
TSHR P16473 2/20 0.35
HPGD P15428 2/20 0.35
PARP1 P09874 1/20 0.35
AR P10275 1/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
ADRA2A P08913 1/20 0.34
CYP2D6 P10635 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695477 0.78 L3MBTL1 (0.42) ALDH1A1TAAR1HRH3TSHRLMNA
SCHEMBL695629 0.77 CALM1 (0.41) CALM1ALDH1A1NR1H2NR1H3DAO
SCHEMBL1855694 0.77 ALDH1A1 (0.42) CALM1ALDH1A1NR1H2NR1H3DAO
SCHEMBL28848167 0.69 RAB9A (0.50) ALDH1A1NR1H2NR1H3DAOGAA
SCHEMBL5449727 0.68 CYP1A2 (0.34) ALDH1A1TYMPNR1H2NR1H3GAA
SCHEMBL855568 0.68 CALM1 (0.39) CALM1ALDH1A1TAAR1HPGDLMNA
SCHEMBL10384790 0.67 CALM1 (0.61) CALM1ALDH1A1TAAR1TSHRHPGD
SCHEMBL11801392 0.65 HCAR2 (0.41) CALM1NR1H2NR1H3DAOTSHR
SCHEMBL7465411 0.64 CALM1 (0.44) CALM1ALDH1A1TYMPNR1H2NR1H3
SCHEMBL8466360 0.63 CALM1 (0.55) CALM1ALDH1A1TAAR1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102405211-B Proline derivatives as cathepsin inhibitors HOFFMANN LA ROCHE 2015-01-21 CN claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US claimed
CN-102405211-A Proline derivatives as cathepsin inhibitors HOFFMANN LA ROCHE 2012-04-04 CN claimed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP claimed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
CN-102405211-B Proline derivatives as cathepsin inhibitors HOFFMANN LA ROCHE 2015-01-21 CN disclosed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
CN-102405211-A Proline derivatives as cathepsin inhibitors HOFFMANN LA ROCHE 2012-04-04 CN disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CALM1 2943/4885ALDH1A1 727/4885TYMP 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.